Related Experiment Video

Updated: Jul 5, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Cystemustine INSERM

B Palmer1

  • 1Auckland University, Cancer Research Laboratory, School of Medicine, Private Bag 92019, Auckland, New Zealand. b.palmer@auckland.ac.nz

Idrugs : the Investigational Drugs Journal
|May 10, 2008
PubMed

Insights

Cystemustine, an anticancer drug, shows potential against various cancers. Its toxicity in mice is linked to circadian rhythms in O6-alkylguanine-DNA alkyltransferase (AGT) activity, suggesting chronotherapy benefits.

Area of Science:

  • Oncology
  • Pharmacology
  • Chronobiology

Background:

  • Cystemustine is a novel chloroethyl-nitrosourea developed as an anticancer agent.
  • It is currently undergoing Phase II clinical trials for several advanced cancers, including melanoma, head and neck, renal, and colorectal cancers.
  • Preliminary data suggests moderate activity against malignant gliomas as a second-line treatment.

Purpose of the Study:

  • To investigate the chronopharmacology of cystemustine, focusing on the influence of circadian dosing time on its toxicity.
  • To explore the relationship between cystemustine's antitumor activity and the circadian rhythm of O6-alkylguanine-DNA alkyltransferase (AGT) in mice.

Main Methods:

  • A study involving 368 synchronized male B6D21F1 mice to assess the impact of circadian dosing on cystemustine toxicity, with leukopenia as a primary endpoint.
  • Analysis of O6-alkylguanine-DNA alkyltransferase (AGT) activity in the liver of 31 mice at six different circadian times.

Main Results:

  • Cystemustine exhibits potent antitumor activity in mice and has a short plasma half-life, suggesting potential for circadian scheduling.
  • A significant circadian rhythm was observed in both cystemustine toxicity and liver AGT activity in mice.
  • Leukopenia was identified as the main hematological toxicity associated with cystemustine treatment.

Conclusions:

  • Circadian rhythms significantly influence cystemustine toxicity and its efficacy.
  • The observed rhythm in liver AGT activity is a key mechanism underlying the chronopharmacology of cystemustine.
  • These findings support the potential for optimizing cystemustine treatment through circadian-timed administration to enhance tolerability and dose intensity.

More Related Videos

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment08:59

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

Related Concept Videos

In-vitro Mutagenesis01:16

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
In vitro Mutagenesis01:16

In vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Modified-Release Drug Delivery Systems: Rate-Programmed I01:22

Modified-Release Drug Delivery Systems: Rate-Programmed I

Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...